<p><em>新的口服液性功能障碍配方将男性性健康作为整体健康的一部分</em></p>
<p>, /PRNewswire/ -- BoomRx，快速增长的国家药品技术平台，简化处方采购和履行，今天宣布推出一种新的口服液性功能障碍（ED）疗法，该疗法结合了伟哥、希爱力和乐威壮——作为目前市场上传统 ED 配方的替代品。</p>
<p>该产品旨在支持医疗诊所和医疗提供者将男性性健康作为综合健康护理的一部分，新产品将西地那非（伟哥）、他达拉非（希爱力）和伐地那非（乐威壮）结合成一种单一配方，采用纳米乳液液体递送系统。</p>
<p>这三种活性成分均为磷酸二酯酶-5（PDE5）抑制剂，这是一类用于治疗 ED 的成熟药物，通过放松血管并增加阴茎的血流量来发挥作用。通过将这些药物结合成一种液体配方，BoomRx 扩展了可供医疗提供者选择的治疗选项，以寻求灵活性、一致性和替代递送形式，以便制定更个性化的治疗计划。</p>
<p>现有的 ED 疗法通常通过片剂、胶囊、凝胶、乳膏、透皮贴片和注射剂进行递送。虽然对许多患者有效，但这些形式可能在吸收变异性、起效时间或患者依从性方面存在挑战。液体递送系统为医疗提供者提供了额外的选择，符合对个性化护理和现代治疗递送的不断变化的期望。</p>
<p>“传统的 ED 疗法未能跟上现代患者期望接受护理的步伐，” BoomRx 创始人兼总裁 Kurt Lunkwitz 表示。“我们的新口服液选项是向无注射、以患者为中心的疗法更广泛转变的一部分，这使医疗提供者在提供个性化护理时拥有更多控制权，同时让患者对他们的 ED 药物在需要时的表现更有信心。”</p>
<p>这种口服液配方利用纳米乳液递送系统，其中活性成分被分散成极小的颗粒。这种方法旨在支持通过口腔和胃肠组织的更有效吸收，相较于传统的固体剂型。与传统的片剂或口服崩解片（ODTs）不同，后者必须先分解才能开始吸收，纳米乳化液可能使活性成分更容易进入血液，从而有助于潜在更快的治疗效果。</p>
<p>性功能障碍影响广泛的患者群体，可能与多种潜在的临床因素相关。到 2025 年，ED 已影响美国数百万患者，且随着年龄的增长，患病率显著上升：65-74 岁年龄段超过 48%，75 岁以上为 52%。此外，年轻男性的患病率也有所上升，约 20 岁以上的男性中有 18% 受到影响，原因包括压力、焦虑和生活方式。</p>
<p>除了与年龄相关的变化，ED 在糖尿病、心血管和代谢疾病患者中也很常见，以及在接受前列腺癌治疗的患者中，手术、放疗或激素治疗可能影响勃起功能。因此，医疗提供者越来越多地将性健康作为持续疾病管理、康复和长期健康规划的一部分进行关注。</p>
<p>“这种口服液 ED 疗法的推出恰逢情人节前夕，医疗诊所看到男性性健康和治疗讨论的季节性关注增加，” Lunkwitz 表示。</p>
<p>新的纳米乳液 ED 配方可通过 BoomRx 为合格的处方提供者提供。</p>
<p>关于 BoomRx</p>
<p>BoomRx 是一个国家药品技术平台，通过一个安全的订单门户统一访问受监管的 503A 和 FDA 注册的 503B 外包设施产品以及其他制造和品牌药物。通过整合多药房工作流程，简化州际运输复杂性，扩大全国访问，推出可预测的统一运费，并改善价格透明度，BoomRx 帮助医疗、健康、远程医疗和医疗水疗实践高效扩展，同时提高运营绩效和患者满意度。有关更多信息，请访问 https://boomrx.com。</p>
<p><strong>媒体联系人：</strong> Jan Sisko</p>
<p>Carabiner Communications</p>
<p>[email protected]</p>
<p>678.591.2022</p>
<p>i Jospeh Daniels, BSc, MD, MPhil, <em>性医学杂志</em>，第 22 卷，第 12 期，2025 年 12 月，2167–2168 页，https://academic.oup.com/jsm/article-abstract/22/12/2167/8277765。</p>
<p>来源 BoomRx</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9Tlk3MjI3NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwODUwUFJfTkVXU19VU1BSX19fX19OWTcyMjc0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9Tlk3MjI3NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwODUwUFJfTkVXU19VU1BSX19fX19OWTcyMjc0"/></p>

<p>BoomRx 推出了一种新的口服液体勃起功能障碍（ED）疗法，将伟哥、希爱力和乐威壮结合为一种单一配方。这一创新产品采用纳米乳液递送系统，以提高吸收率和加快治疗效果。该疗法旨在提升男性的性健康，作为整体健康的一部分，解决了传统 ED 治疗的局限性。此次发布恰逢情人节前夕，季节性亲密关系讨论增多，突显了男性健康中对个性化护理日益增长的关注</p>

<p><em>New ED Formulation Puts Focus on Men's Sexual Health as Part of Overall Wellness</em></p>
<div class="lb-trans"><p><em>新的口服液性功能障碍配方将男性性健康作为整体健康的一部分</em></p>
</div><p>, /PRNewswire/ -- BoomRx, the fastest-growing national pharmaceutical technology platform that simplifies prescription sourcing and fulfillment, today announced the availability of a new oral liquid erectile dysfunction (ED) therapy that combines Viagra, Cialis and Levitra—offered as an alternative to conventional ED formulations currently on the market.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- BoomRx，快速增长的国家药品技术平台，简化处方采购和履行，今天宣布推出一种新的口服液性功能障碍（ED）疗法，该疗法结合了伟哥、希爱力和乐威壮——作为目前市场上传统 ED 配方的替代品。</p>
</div><p>Developed to support medical clinics and healthcare providers addressing men's sexual health as part of comprehensive wellness care, the new offering combines sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) into a single formulation using a nanoemulsion liquid delivery system.</p>
<div class="lb-trans"><p>该产品旨在支持医疗诊所和医疗提供者将男性性健康作为综合健康护理的一部分，新产品将西地那非（伟哥）、他达拉非（希爱力）和伐地那非（乐威壮）结合成一种单一配方，采用纳米乳液液体递送系统。</p>
</div><p>All three active ingredients are phosphodiesterase-5 (PDE5) inhibitors, a well-established class of medications used to treat ED by relaxing blood vessels and increasing blood flow to the penis. By combining these agents into a single liquid formulation, BoomRx expands therapeutic options available to providers seeking flexibility, consistency, and alternative delivery formats for more individualized treatment plans.</p>
<div class="lb-trans"><p>这三种活性成分均为磷酸二酯酶-5（PDE5）抑制剂，这是一类用于治疗 ED 的成熟药物，通过放松血管并增加阴茎的血流量来发挥作用。通过将这些药物结合成一种液体配方，BoomRx 扩展了可供医疗提供者选择的治疗选项，以寻求灵活性、一致性和替代递送形式，以便制定更个性化的治疗计划。</p>
</div><p>Existing ED therapies are commonly delivered through tablets, capsules, gels, creams, transdermal patches and injectables. While effective for many patients, these formats may present challenges related to absorption variability, onset timing, or patient adherence. Liquid delivery systems offer healthcare providers an additional option that aligns with evolving expectations around individualized care and modern treatment delivery.</p>
<div class="lb-trans"><p>现有的 ED 疗法通常通过片剂、胶囊、凝胶、乳膏、透皮贴片和注射剂进行递送。虽然对许多患者有效，但这些形式可能在吸收变异性、起效时间或患者依从性方面存在挑战。液体递送系统为医疗提供者提供了额外的选择，符合对个性化护理和现代治疗递送的不断变化的期望。</p>
</div><p>&#34;Traditional ED therapies haven't kept pace with how modern patients expect to receive care,&#34; said Kurt Lunkwitz, founder and president of BoomRx. &#34;Our new oral liquid option is part of a broader shift toward injection-free, patient-friendly therapies that give healthcare providers more control in how they provide personalized care while giving their patients more confidence in how their ED medications will perform when they need it.&#34;</p>
<div class="lb-trans"><p>“传统的 ED 疗法未能跟上现代患者期望接受护理的步伐，” BoomRx 创始人兼总裁 Kurt Lunkwitz 表示。“我们的新口服液选项是向无注射、以患者为中心的疗法更广泛转变的一部分，这使医疗提供者在提供个性化护理时拥有更多控制权，同时让患者对他们的 ED 药物在需要时的表现更有信心。”</p>
</div><p>The oral liquid formulation utilizes a nanoemulsion delivery system in which the active ingredients are dispersed into extremely small particles. This approach is designed to support more efficient absorption through the oral and gastrointestinal tissues compared to conventional solid dosage forms. Unlike traditional tablets or orally disintegrating tablets (ODTs), which must first break down before absorption can begin, the nanoemulsified liquid may allow the active ingredients to enter the bloodstream more readily, contributing to a potentially faster onset of therapeutic effect.</p>
<div class="lb-trans"><p>这种口服液配方利用纳米乳液递送系统，其中活性成分被分散成极小的颗粒。这种方法旨在支持通过口腔和胃肠组织的更有效吸收，相较于传统的固体剂型。与传统的片剂或口服崩解片（ODTs）不同，后者必须先分解才能开始吸收，纳米乳化液可能使活性成分更容易进入血液，从而有助于潜在更快的治疗效果。</p>
</div><p>Erectile dysfunction affects a broad patient population and may be associated with a range of underlying clinical factors. As of 2025, ED had affected millions in the United States, with prevalence rising significantly with age: more than 48 percent for ages 65-74 and 52 percent for 75+. Furthermore, increases have also been noted in younger men with approximately 18 percent of men over age 20 being affected due to factors like stress, anxiety, and lifestyle.i</p>
<div class="lb-trans"><p>性功能障碍影响广泛的患者群体，可能与多种潜在的临床因素相关。到 2025 年，ED 已影响美国数百万患者，且随着年龄的增长，患病率显著上升：65-74 岁年龄段超过 48%，75 岁以上为 52%。此外，年轻男性的患病率也有所上升，约 20 岁以上的男性中有 18% 受到影响，原因包括压力、焦虑和生活方式。</p>
</div><p>In addition to age-related changes, ED is commonly seen in men with diabetes, cardiovascular and metabolic conditions, as well as in patients following prostate cancer treatment, where surgery, radiation, or hormone therapy may impact erectile function. As a result, sexual health is increasingly addressed by healthcare providers as part of ongoing disease management, recovery, and long-term wellness planning.</p>
<div class="lb-trans"><p>除了与年龄相关的变化，ED 在糖尿病、心血管和代谢疾病患者中也很常见，以及在接受前列腺癌治疗的患者中，手术、放疗或激素治疗可能影响勃起功能。因此，医疗提供者越来越多地将性健康作为持续疾病管理、康复和长期健康规划的一部分进行关注。</p>
</div><p>&#34;The introduction of this oral liquid ED therapy coincides with seasonal discussions around intimacy and relationships ahead of Valentine's Day, as medical clinics see increased seasonal focus on men's sexual health and treatment discussions,&#34; said Lunkwitz.</p>
<div class="lb-trans"><p>“这种口服液 ED 疗法的推出恰逢情人节前夕，医疗诊所看到男性性健康和治疗讨论的季节性关注增加，” Lunkwitz 表示。</p>
</div><p>The new nanonemulsion ED formulation is available through BoomRx for qualified prescribing providers.</p>
<div class="lb-trans"><p>新的纳米乳液 ED 配方可通过 BoomRx 为合格的处方提供者提供。</p>
</div><p>About BoomRx</p>
<div class="lb-trans"><p>关于 BoomRx</p>
</div><p>BoomRx is a national pharmaceutical technology platform that unifies access to regulated 503A and FDA-registered 503B outsourcing facility products as well as other manufactured and brand medications through a single, secure ordering portal. By consolidating multi-pharmacy workflows, simplifying state-by-state shipping complexity, expanding national access, introducing predictable flat-rate shipping, and improving price transparency, BoomRx helps medical, wellness, telemedicine, and med-spa practices scale efficiently while improving operational performance and patient satisfaction. For more information, please visit https://boomrx.com.</p>
<div class="lb-trans"><p>BoomRx 是一个国家药品技术平台，通过一个安全的订单门户统一访问受监管的 503A 和 FDA 注册的 503B 外包设施产品以及其他制造和品牌药物。通过整合多药房工作流程，简化州际运输复杂性，扩大全国访问，推出可预测的统一运费，并改善价格透明度，BoomRx 帮助医疗、健康、远程医疗和医疗水疗实践高效扩展，同时提高运营绩效和患者满意度。有关更多信息，请访问 https://boomrx.com。</p>
</div><p><strong>Media contact:</strong> Jan Sisko</p>
<div class="lb-trans"><p><strong>媒体联系人：</strong> Jan Sisko</p>
</div><p>Carabiner Communications</p>
<div class="lb-trans"><p>Carabiner Communications</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>678.591.2022</p>
<div class="lb-trans"><p>678.591.2022</p>
</div><p>i Jospeh Daniels, BSc, MD, MPhil, <em>The Journal of Sexual Medicine</em>, Volume 22, Issue 12, December 2025, Pages 2167–2168, https://academic.oup.com/jsm/article-abstract/22/12/2167/8277765.</p>
<div class="lb-trans"><p>i Jospeh Daniels, BSc, MD, MPhil, <em>性医学杂志</em>，第 22 卷，第 12 期，2025 年 12 月，2167–2168 页，https://academic.oup.com/jsm/article-abstract/22/12/2167/8277765。</p>
</div><p>SOURCE BoomRx</p>
<div class="lb-trans"><p>来源 BoomRx</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9Tlk3MjI3NCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwODUwUFJfTkVXU19VU1BSX19fX19OWTcyMjc0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY72274&amp;Transmission_Id=202601280850PR_NEWS_USPR_____NY72274&amp;DateId=20260128"/></p>

08:50 ET
			
			
				Just in Time for Valentine's Day, BoomRx Launches Oral Liquid Erectile-Dysfunction Therapy

- BoomRx 发布新型口服液体勃起功能障碍疗法，结合了 Viagra、Cialis 和 Levitra。  
- 该疗法使用纳米乳液递送系统，旨在提高吸收效率和治疗效果。  
- 此产品响应男性性健康需求，支持个性化医疗选择。

prnewswire

美国医疗保健供应商 ETF - iShares

标普生物技术 ETF - SPDR

GoodRx

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

礼来

辉瑞

医疗业 ETF - Vanguard

2 倍做多纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

葛兰素史克

Invesco Nasdaq Biotechnology ETF

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

拜耳(ADR)

标普全球医疗股指数 ETF - iShares

美国制药 ETF - iShares

正值情人节之际，BoomRx 推出了口服液体勃起功能障碍治疗药物